{"protocolSection":{"identificationModule":{"nctId":"NCT06440980","orgStudyIdInfo":{"id":"18617"},"secondaryIdInfos":[{"id":"J2A-MC-GZPI","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight","officialTitle":"A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy."},"statusModule":{"statusVerifiedDate":"2026-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-06-02","type":"ACTUAL"},"completionDateStruct":{"date":"2025-06-02","type":"ACTUAL"},"studyFirstSubmitDate":"2024-05-29","studyFirstSubmitQcDate":"2024-05-29","studyFirstPostDateStruct":{"date":"2024-06-04","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-04-30","resultsFirstSubmitQcDate":"2026-06-20","resultsFirstPostDateStruct":{"date":"2026-07-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-06-20","lastUpdatePostDateStruct":{"date":"2026-07-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated.\n\nThe study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period."},"conditionsModule":{"conditions":["Healthy","Obese","Overweight","Obesity"],"keywords":["Pharmacokinetics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":533,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally once daily (QD) across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: 1 mg (Capsule)\n* Period 2: Dose Level 2 (Tablet)\n* Period 3: Dose Level 1 (Tablet)\n* Period 4: Dose Level 3 (Tablet)\n* Period 5: 3 mg (Capsule)\n* Period 6: Dose Level 5 (Tablet)\n* Period 7: Dose Level 4 (Tablet)\n* Period 8: Dose Level 6 (Tablet)\n* Period 9: 6 mg (Capsule)\n* Period 10: Dose Level 8 (Tablet)\n* Period 11: Dose Level 7 (Tablet)\n* Period 12: Dose Level 9 (Tablet)","interventionNames":["Drug: Orforglipron"]},{"label":"Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: Dose Level 2 (Tablet)\n* Period 2: 1 mg (Capsule)\n* Period 3: Dose Level 3 (Tablet)\n* Period 4: Dose Level 1 (Tablet)\n* Period 5: Dose Level 5 (Tablet)\n* Period 6: 3 mg (Capsule)\n* Period 7: Dose Level 6 (Tablet)\n* Period 8: Dose Level 4 (Tablet)\n* Period 9: Dose Level 8 (Tablet)\n* Period 10: 6 mg (Capsule)\n* Period 11: Dose Level 9 (Tablet)\n* Period 12: Dose Level 7 (Tablet)","interventionNames":["Drug: Orforglipron"]},{"label":"Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: Dose Level 1 (Tablet)\n* Period 2: Dose Level 3 (Tablet)\n* Period 3: 1 mg (Capsule)\n* Period 4: Dose Level 2 (Tablet)\n* Period 5: Dose Level 4 (Tablet)\n* Period 6: Dose Level 6 (Tablet)\n* Period 7: 3 mg (Capsule)\n* Period 8: Dose Level 5 (Tablet)\n* Period 9: Dose Level 7 (Tablet)\n* Period 10: Dose Level 9 (Tablet)\n* Period 11: 6 mg (Capsule)\n* Period 12: Dose Level 8 (Tablet)","interventionNames":["Drug: Orforglipron"]},{"label":"Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: Dose Level 3 (Tablet)\n* Period 2: Dose Level 1 (Tablet)\n* Period 3: Dose Level 2 (Tablet)\n* Period 4: 1 mg (Capsule)\n* Period 5: Dose Level 6 (Tablet)\n* Period 6: Dose Level 4 (Tablet)\n* Period 7: Dose Level 5 (Tablet)\n* Period 8: 3 mg (Capsule)\n* Period 9: Dose Level 9 (Tablet)\n* Period 10: Dose Level 7 (Tablet)\n* Period 11: Dose Level 8 (Tablet)\n* Period 12: 6 mg (Capsule)","interventionNames":["Drug: Orforglipron"]},{"label":"Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: 12 mg (Capsule)\n* Period 8: Dose Level 11 (Tablet)\n* Period 9: Dose Level 10 (Tablet)\n* Period 10: Dose Level 12 (Tablet)\n* Period 11: 24 mg (Capsule)\n* Period 12: Dose Level 14 (Tablet)\n* Period 13: Dose Level 13 (Tablet)\n* Period 14: Dose Level 16 (Tablet)\n* Period 15: 36 mg (Capsule)\n* Period 16: Dose Level 17 (Tablet)\n* Period 17: Dose Level 15 (Tablet)\n* Period 18: Dose Level 18 (Tablet)","interventionNames":["Drug: Orforglipron"]},{"label":"Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: Dose Level 11 (Tablet)\n* Period 8: 12 mg (Capsule)\n* Period 9: Dose Level 12 (Tablet)\n* Period 10: Dose Level 10 (Tablet)\n* Period 11: Dose Level 14 (Tablet)\n* Period 12: 24 mg (Capsule)\n* Period 13: Dose Level 16 (Tablet)\n* Period 14: Dose Level 13 (Tablet)\n* Period 15: Dose Level 17 (Tablet)\n* Period 16: 36 mg (Capsule)\n* Period 17: Dose Level 18 (Tablet)\n* Period 18: Dose Level 15 (Tablet)","interventionNames":["Drug: Orforglipron"]},{"label":"Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: Dose Level 10 (Tablet)\n* Period 8: Dose Level 12 (Tablet)\n* Period 9: 12 mg (Capsule)\n* Period 10: Dose Level 11 (Tablet)\n* Period 11: Dose Level 13 (Tablet)\n* Period 12: Dose Level 16 (Tablet)\n* Period 13: 24 mg (Capsule)\n* Period 14: Dose Level 14 (Tablet)\n* Period 15: Dose Level 15 (Tablet)\n* Period 16: Dose Level 18 (Tablet)\n* Period 17: 36 mg (Capsule)\n* Period 18: Dose Level 17 (Tablet)","interventionNames":["Drug: Orforglipron"]},{"label":"Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: Dose Level 12 (Tablet)\n* Period 8: Dose Level 10 (Tablet)\n* Period 9: Dose Level 11 (Tablet)\n* Period 10: 12 mg (Capsule)\n* Period 11: Dose Level 16 (Tablet)\n* Period 12: Dose Level 13 (Tablet)\n* Period 13: Dose Level 14 (Tablet)\n* Period 14: 24 mg (Capsule)\n* Period 15: Dose Level 18 (Tablet)\n* Period 16: Dose Level 15 (Tablet)\n* Period 17: Dose Level 17 (Tablet)\n* Period 18: 36 mg (Capsule)","interventionNames":["Drug: Orforglipron"]},{"label":"Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: 1 mg (Capsule- First Treatment)\n* Period 2: 1 mg (Capsule- Second Treatment)\n* Period 3: 0.8 mg (Tablet)\n* Period 4: 3 mg (Capsule- First Treatment)\n* Period 5: 3 mg (Capsule- Second Treatment)\n* Period 6: 2.5 mg (Tablet)\n* Period 7: 6 mg (Capsule- First Treatment)\n* Period 8: 6 mg (Capsule- Second Treatment)\n* Period 9: 5.5 mg (Tablet)","interventionNames":["Drug: Orforglipron"]},{"label":"Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: 1 mg (Capsule- First Treatment)\n* Period 2: 0.8 mg (Tablet)\n* Period 3: 1 mg (Capsule- Second Treatment)\n* Period 4: 3 mg (Capsule- First Treatment)\n* Period 5: 2.5 mg (Tablet)\n* Period 6: 3 mg (Capsule- Second Treatment)\n* Period 7: 6 mg (Capsule- First Treatment)\n* Period 8: 5.5 mg (Tablet)\n* Period 9: 6 mg (Capsule- Second Treatment)","interventionNames":["Drug: Orforglipron"]},{"label":"Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: 0.8 mg (Tablet)\n* Period 2: 1 mg (Capsule- First Treatment)\n* Period 3: 1 mg (Capsule- Second Treatment)\n* Period 4: 2.5 mg (Tablet)\n* Period 5: 3 mg (Capsule- First Treatment)\n* Period 6: 3 mg (Capsule- Second Treatment)\n* Period 7: 5.5 mg (Tablet)\n* Period 8: 6 mg (Capsule- First Treatment)\n* Period 9: 6 mg (Capsule- Second Treatment)","interventionNames":["Drug: Orforglipron"]},{"label":"Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \\[Capsule\\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: 12 mg (Capsule- First Treatment)\n* Period 8: 12 mg (Capsule- Second Treatment)\n* Period 9: 9 mg (Tablet)\n* Period 10: 24 mg (Capsule- First Treatment)\n* Period 11: 24 mg (Capsule- Second Treatment)\n* Period 12: 14.5 mg (Tablet)\n* Period 13: 36 mg (Capsule- First Treatment)\n* Period 14: 36 mg (Capsule- Second Treatment)\n* Period 15: 17.2 mg (Tablet)","interventionNames":["Drug: Orforglipron"]},{"label":"Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \\[Capsule\\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: 12 mg (Capsule- First Treatment)\n* Period 8: 9 mg (Tablet)\n* Period 9: 12 mg (Capsule- Second Treatment)\n* Period 10: 24 mg (Capsule- First Treatment)\n* Period 11: 14.5 mg (Tablet)\n* Period 12: 24 mg (Capsule- Second Treatment)\n* Period 13: 36 mg (Capsule- First Treatment)\n* Period 14: 17.2 mg (Tablet)\n* Period 15: 36 mg (Capsule- Second Treatment)","interventionNames":["Drug: Orforglipron"]},{"label":"Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)","type":"EXPERIMENTAL","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \\[Capsule\\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: 9 mg (Tablet)\n* Period 8: 12 mg (Capsule- First Treatment)\n* Period 9: 12 mg (Capsule- Second Treatment)\n* Period 10: 14.5 mg (Tablet)\n* Period 11: 24 mg (Capsule- First Treatment)\n* Period 12: 24 mg (Capsule- Second Treatment)\n* Period 13: 17.2 mg (Tablet)\n* Period 14: 36 mg (Capsule- First Treatment)\n* Period 15: 36 mg (Capsule- Second Treatment)","interventionNames":["Drug: Orforglipron"]}],"interventions":[{"type":"DRUG","name":"Orforglipron","description":"Administered orally","armGroupLabels":["Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)","Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)","Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)","Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)","Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)","Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)","Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)","Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)","Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)","Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)","Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)","Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)","Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)","Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)"],"otherNames":["LY3502970"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7","description":"PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC\\[0-tau\\] on Day 7.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)"},{"measure":"Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7","description":"PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants who are overtly healthy as determined by medical history and physical examination.\n* Have a stable body weight for one month prior to screening (less than or equal to 5 percent body weight gain or loss) and Body Mass Index (BMI) in range of 27 to 40 kilogram per meter square (kg/m²).\n* Participants must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.\n* Have venous access sufficient to allow for blood sampling.\n\nExclusion Criteria:\n\n* Have hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater.\n* Have a history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or other significant active, uncontrolled medical conditions.\n* Have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years.\n* Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome.\n* Have known clinically significant gastric emptying abnormality.\n* Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)\n* Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer.\n* Have an abnormal 12-lead electrocardiogram (ECG) at screening.\n* Have history of pancreatitis.\n* Judged by the study investigator to be at serious suicidal risk and have answered \"Yes\" to either question 4 or 5 on the Columbia-Suicide Severity Rating Scale \\[C-SSRS\\]).\n* Have difficulty swallowing capsules or tablets.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Anaheim Clinical Trials, LLC","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Collaborative Neuroscience Research, LLC","city":"Los Alamitos","state":"California","zip":"90720","country":"United States","geoPoint":{"lat":33.80307,"lon":-118.07256}},{"facility":"Fortrea Clinical Research Unit","city":"Daytona Beach","state":"Florida","zip":"32117","country":"United States","geoPoint":{"lat":29.21081,"lon":-81.02283}},{"facility":"Altasciences Company Inc.","city":"Overland Park","state":"Kansas","zip":"66212","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"QPS","city":"Springfield","state":"Missouri","zip":"65802","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"Fortrea Clinical Research Unit","city":"Dallas","state":"Texas","zip":"75247","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Fortrea Clinical Research Unit","city":"Madison","state":"Wisconsin","zip":"53704","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}}]},"referencesModule":{"references":[{"pmid":"41994902","type":"DERIVED","citation":"Ma X, Li YG, Raha S, Sperry DC, Coutant DE, Bhattachar S. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes Obes Metab. 2026 Jul;28(7):5803-5809. doi: 10.1111/dom.70783. Epub 2026 Apr 17."}],"seeAlsoLinks":[{"label":"A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight","url":"https://trials.lilly.com/en-US/trial/495475"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Part A: Cohorts 1A and 2A (each N=52) followed a 4-sequence crossover (12 and 18 periods); Cohort 2A included home (Periods 1-6) and inpatient dosing (Periods 7-18). Part B: Cohorts 1B (N=216; 9 periods) and 2B (N=213; 15 periods) followed a 3-sequence crossover; Cohort 2B included home (Periods 1-6) and inpatient dosing (Periods 7-15).","recruitmentDetails":"This study enrolled 533 participants across 4 mutually exclusive cohorts in 2 parts: Part A (pilot relative bioavailability; Cohorts 1A and 2A) and Part B (bioequivalence; Cohorts 1B and 2B).\n\nAs per sponsor decision, for Part A tablet (Cohorts 1A and 2A), dose levels are presented as Dose Level 1 through Dose Level 18, where Dose Level 1 represents the lowest dose and Dose Level 18 represents the highest dose.","groups":[{"id":"FG000","title":"Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)","description":"Participants received LY3502970 orally once daily (QD) across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: 1 mg (Capsule)\n* Period 2: Dose Level 2 (Tablet)\n* Period 3: Dose Level 1 (Tablet)\n* Period 4: Dose Level 3 (Tablet)\n* Period 5: 3 mg (Capsule)\n* Period 6: Dose Level 5 (Tablet)\n* Period 7: Dose Level 4 (Tablet)\n* Period 8: Dose Level 6 (Tablet)\n* Period 9: 6 mg (Capsule)\n* Period 10: Dose Level 8 (Tablet)\n* Period 11: Dose Level 7 (Tablet)\n* Period 12: Dose Level 9 (Tablet)"},{"id":"FG001","title":"Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: Dose Level 2 (Tablet)\n* Period 2: 1 mg (Capsule)\n* Period 3: Dose Level 3 (Tablet)\n* Period 4: Dose Level 1 (Tablet)\n* Period 5: Dose Level 5 (Tablet)\n* Period 6: 3 mg (Capsule)\n* Period 7: Dose Level 6 (Tablet)\n* Period 8: Dose Level 4 (Tablet)\n* Period 9: Dose Level 8 (Tablet)\n* Period 10: 6 mg (Capsule)\n* Period 11: Dose Level 9 (Tablet)\n* Period 12: Dose Level 7 (Tablet)"},{"id":"FG002","title":"Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: Dose Level 1 (Tablet)\n* Period 2: Dose Level 3 (Tablet)\n* Period 3: 1 mg (Capsule)\n* Period 4: Dose Level 2 (Tablet)\n* Period 5: Dose Level 4 (Tablet)\n* Period 6: Dose Level 6 (Tablet)\n* Period 7: 3 mg (Capsule)\n* Period 8: Dose Level 5 (Tablet)\n* Period 9: Dose Level 7 (Tablet)\n* Period 10: Dose Level 9 (Tablet)\n* Period 11: 6 mg (Capsule)\n* Period 12: Dose Level 8 (Tablet)"},{"id":"FG003","title":"Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: Dose Level 3 (Tablet)\n* Period 2: Dose Level 1 (Tablet)\n* Period 3: Dose Level 2 (Tablet)\n* Period 4: 1 mg (Capsule)\n* Period 5: Dose Level 6 (Tablet)\n* Period 6: Dose Level 4 (Tablet)\n* Period 7: Dose Level 5 (Tablet)\n* Period 8: 3 mg (Capsule)\n* Period 9: Dose Level 9 (Tablet)\n* Period 10: Dose Level 7 (Tablet)\n* Period 11: Dose Level 8 (Tablet)\n* Period 12: 6 mg (Capsule)"},{"id":"FG004","title":"Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: 12 mg (Capsule)\n* Period 8: Dose Level 11 (Tablet)\n* Period 9: Dose Level 10 (Tablet)\n* Period 10: Dose Level 12 (Tablet)\n* Period 11: 24 mg (Capsule)\n* Period 12: Dose Level 14 (Tablet)\n* Period 13: Dose Level 13 (Tablet)\n* Period 14: Dose Level 15 (Tablet)\n* Period 15: 36 mg (Capsule)\n* Period 16: Dose Level 17 (Tablet)\n* Period 17: Dose Level 16 (Tablet)\n* Period 18: Dose Level 18 (Tablet)"},{"id":"FG005","title":"Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: Dose Level 11 (Tablet)\n* Period 8: 12 mg (Capsule)\n* Period 9: Dose Level 12 (Tablet)\n* Period 10: Dose Level 10 (Tablet)\n* Period 11: Dose Level 14 (Tablet)\n* Period 12: 24 mg (Capsule)\n* Period 13: Dose Level 15 (Tablet)\n* Period 14: Dose Level 13 (Tablet)\n* Period 15: Dose Level 17 (Tablet)\n* Period 16: 36 mg (Capsule)\n* Period 17: Dose Level 18 (Tablet)\n* Period 18: Dose Level 16 (Tablet)"},{"id":"FG006","title":"Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: Dose Level 10 (Tablet)\n* Period 8: Dose Level 12 (Tablet)\n* Period 9: 12 mg (Capsule)\n* Period 10: Dose Level 11 (Tablet)\n* Period 11: Dose Level 13 (Tablet)\n* Period 12: Dose Level 15 (Tablet)\n* Period 13: 24 mg (Capsule)\n* Period 14: Dose Level 14 (Tablet)\n* Period 15: Dose Level 16 (Tablet)\n* Period 16: Dose Level 18 (Tablet)\n* Period 17: 36 mg (Capsule)\n* Period 18: Dose Level 17 (Tablet)"},{"id":"FG007","title":"Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: Dose Level 12 (Tablet)\n* Period 8: Dose Level 10 (Tablet)\n* Period 9: Dose Level 11 (Tablet)\n* Period 10: 12 mg (Capsule)\n* Period 11: Dose Level 15 (Tablet)\n* Period 12: Dose Level 13 (Tablet)\n* Period 13: Dose Level 14 (Tablet)\n* Period 14: 24 mg (Capsule)\n* Period 15: Dose Level 18 (Tablet)\n* Period 16: Dose Level 15 (Tablet)\n* Period 17: Dose Level 17 (Tablet)\n* Period 18: 36 mg (Capsule)"},{"id":"FG008","title":"Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: 1 mg (Capsule- First Treatment)\n* Period 2: 1 mg (Capsule- Second Treatment)\n* Period 3: 0.8 mg (Tablet)\n* Period 4: 3 mg (Capsule- First Treatment)\n* Period 5: 3 mg (Capsule- Second Treatment)\n* Period 6: 2.5 mg (Tablet)\n* Period 7: 6 mg (Capsule- First Treatment)\n* Period 8: 6 mg (Capsule- Second Treatment)\n* Period 9: 5.5 mg (Tablet)"},{"id":"FG009","title":"Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: 1 mg (Capsule- First Treatment)\n* Period 2: 0.8 mg (Tablet)\n* Period 3: 1 mg (Capsule- Second Treatment)\n* Period 4: 3 mg (Capsule- First Treatment)\n* Period 5: 2.5 mg (Tablet)\n* Period 6: 3 mg (Capsule- Second Treatment)\n* Period 7: 6 mg (Capsule- First Treatment)\n* Period 8: 5.5 mg (Tablet)\n* Period 9: 6 mg (Capsule- Second Treatment)"},{"id":"FG010","title":"Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)","description":"Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows:\n\n* Period 1: 0.8 mg (Tablet)\n* Period 2: 1 mg (Capsule- First Treatment)\n* Period 3: 1 mg (Capsule- Second Treatment)\n* Period 4: 2.5 mg (Tablet)\n* Period 5: 3 mg (Capsule- First Treatment)\n* Period 6: 3 mg (Capsule- Second Treatment)\n* Period 7: 5.5 mg (Tablet)\n* Period 8: 6 mg (Capsule- First Treatment)\n* Period 9: 6 mg (Capsule- Second Treatment)"},{"id":"FG011","title":"Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \\[Capsule\\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: 12 mg (Capsule- First Treatment)\n* Period 8: 12 mg (Capsule- Second Treatment)\n* Period 9: 9 mg (Tablet)\n* Period 10: 24 mg (Capsule- First Treatment)\n* Period 11: 24 mg (Capsule- Second Treatment)\n* Period 12: 14.5 mg (Tablet)\n* Period 13: 36 mg (Capsule- First Treatment)\n* Period 14: 36 mg (Capsule- Second Treatment)\n* Period 15: 17.2 mg (Tablet)"},{"id":"FG012","title":"Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \\[Capsule\\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: 12 mg (Capsule- First Treatment)\n* Period 8: 9 mg (Tablet)\n* Period 9: 12 mg (Capsule- Second Treatment)\n* Period 10: 24 mg (Capsule- First Treatment)\n* Period 11: 14.5 mg (Tablet)\n* Period 12: 24 mg (Capsule- Second Treatment)\n* Period 13: 36 mg (Capsule- First Treatment)\n* Period 14: 17.2 mg (Tablet)\n* Period 15: 36 mg (Capsule- Second Treatment)"},{"id":"FG013","title":"Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)","description":"Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \\[Capsule\\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows:\n\n* Period 7: 9 mg (Tablet)\n* Period 8: 12 mg (Capsule- First Treatment)\n* Period 9: 12 mg (Capsule- Second Treatment)\n* Period 10: 14.5 mg (Tablet)\n* Period 11: 24 mg (Capsule- First Treatment)\n* Period 12: 24 mg (Capsule- Second Treatment)\n* Period 13: 17.2 mg (Tablet)\n* Period 14: 36 mg (Capsule- First Treatment)\n* Period 15: 36 mg (Capsule- Second Treatment)"}],"periods":[{"title":"Cohort 1A","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 1","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 2","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 3","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 4","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 5","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 6","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 7","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 8","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 9","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 10","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 11","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 12","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}]},{"title":"Cohort 2A","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Home-Dosing (Period 1-6)","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 7","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 8","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 9","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 10","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 11","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 12","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 13","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 14","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 15","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 16","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 17","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 18","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}]},{"title":"Cohort 1B","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"72"},{"groupId":"FG009","numSubjects":"72"},{"groupId":"FG010","numSubjects":"72"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 1","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"72"},{"groupId":"FG009","numSubjects":"72"},{"groupId":"FG010","numSubjects":"72"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 2","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"71"},{"groupId":"FG009","numSubjects":"70"},{"groupId":"FG010","numSubjects":"71"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 3","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"71"},{"groupId":"FG009","numSubjects":"69"},{"groupId":"FG010","numSubjects":"71"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 4","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"71"},{"groupId":"FG009","numSubjects":"69"},{"groupId":"FG010","numSubjects":"71"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 5","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"71"},{"groupId":"FG009","numSubjects":"68"},{"groupId":"FG010","numSubjects":"70"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 6","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"71"},{"groupId":"FG009","numSubjects":"67"},{"groupId":"FG010","numSubjects":"69"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 7","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"70"},{"groupId":"FG009","numSubjects":"67"},{"groupId":"FG010","numSubjects":"68"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 8","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"69"},{"groupId":"FG009","numSubjects":"66"},{"groupId":"FG010","numSubjects":"66"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Period 9","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"69"},{"groupId":"FG009","numSubjects":"65"},{"groupId":"FG010","numSubjects":"66"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"69"},{"groupId":"FG009","numSubjects":"64"},{"groupId":"FG010","numSubjects":"66"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"8"},{"groupId":"FG010","numSubjects":"6"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"5"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}]},{"title":"Cohort 2B","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"87"},{"groupId":"FG012","numSubjects":"63"},{"groupId":"FG013","numSubjects":"63"}]},{"type":"Period 1-6","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"87"},{"groupId":"FG012","numSubjects":"63"},{"groupId":"FG013","numSubjects":"63"}]},{"type":"Period 7","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"63"},{"groupId":"FG012","numSubjects":"62"},{"groupId":"FG013","numSubjects":"63"}]},{"type":"Period 8","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"62"},{"groupId":"FG012","numSubjects":"61"},{"groupId":"FG013","numSubjects":"61"}]},{"type":"Period 9","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"62"},{"groupId":"FG012","numSubjects":"61"},{"groupId":"FG013","numSubjects":"59"}]},{"type":"Period 10","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"61"},{"groupId":"FG012","numSubjects":"61"},{"groupId":"FG013","numSubjects":"59"}]},{"type":"Period 11","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"60"},{"groupId":"FG012","numSubjects":"61"},{"groupId":"FG013","numSubjects":"59"}]},{"type":"Period 12","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"60"},{"groupId":"FG012","numSubjects":"61"},{"groupId":"FG013","numSubjects":"58"}]},{"type":"Period 13","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"59"},{"groupId":"FG012","numSubjects":"60"},{"groupId":"FG013","numSubjects":"58"}]},{"type":"Period 14","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"58"},{"groupId":"FG012","numSubjects":"60"},{"groupId":"FG013","numSubjects":"57"}]},{"type":"Period 15","comment":"All enrolled participants who received at least one dose of study drug.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"58"},{"groupId":"FG012","numSubjects":"60"},{"groupId":"FG013","numSubjects":"57"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"58"},{"groupId":"FG012","numSubjects":"60"},{"groupId":"FG013","numSubjects":"56"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"29"},{"groupId":"FG012","numSubjects":"3"},{"groupId":"FG013","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"9"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"4"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"8"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"2"}]},{"type":"Non-Compliance With Study Drug","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Screen Failure","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"2"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Protocol Deviation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"3"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All enrolled participants.","groups":[{"id":"BG000","title":"Part A: LY3502970 Oral Administration - Cohort 1A","description":"* Participants in Cohort 1A received LY3502970 administered orally once daily as capsules or tablets at dose levels corresponding to capsule doses of 1 mg, 3 mg, and 6 mg.\n* Participants received each of the three capsule doses and tablets at dose strengths corresponding to the capsule dose levels.\n* Study treatment was administered across 12 dosing periods, with each dosing period lasting 7 days."},{"id":"BG001","title":"Part A: LY3502970 Oral Administration - Cohort 2A","description":"* Participants in Cohort 2A received LY3502970 administered orally once daily as capsules or tablets at dose levels corresponding to capsule doses of 12 mg, 24 mg, and 36 mg.\n* Treatment included an initial 6-period at-home dosing phase with capsule dosing only, followed by 12 inpatient dosing periods.\n* During the inpatient period, participants received each of the three capsule doses and tablets at dose strengths corresponding to the capsule dose levels.\n* Overall, study treatment was administered across a total of 18 dosing periods (6 at-home and 12 inpatient), each lasting 7 days."},{"id":"BG002","title":"Part B: LY3502970 Oral Administration - Cohort 1B","description":"* Participants in Cohort 1B received LY3502970 administered orally once daily as capsules or tablets at dose levels corresponding to capsule doses of 1 mg, 3 mg, and 6 mg.\n* Participants received each of the two capsule doses and tablets at dose strengths corresponding to the capsule dose levels.\n* Study treatment was administered across 9 dosing periods, with each dosing period lasting 7 days."},{"id":"BG003","title":"Part B: LY3502970 Oral Administration - Cohort 2B","description":"* Participants in Cohort 2B received LY3502970 administered orally once daily as capsules or tablets at dose levels corresponding to capsule doses of 12 mg, 24 mg, and 36 mg.\n* Treatment included an initial 6-period at-home dosing phase with capsule dosing only, followed by 12 inpatient dosing periods.\n* During the inpatient period, participants received each of the two capsule doses and tablets at dose strengths corresponding to the capsule dose levels.\n* Overall, study treatment was administered across a total of 15 dosing periods (6 at-home and 9 inpatient), each lasting 7 days."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"216"},{"groupId":"BG003","value":"213"},{"groupId":"BG004","value":"533"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45.9","spread":"10.74"},{"groupId":"BG001","value":"42.8","spread":"10.28"},{"groupId":"BG002","value":"44.7","spread":"11.12"},{"groupId":"BG003","value":"42.1","spread":"10.50"},{"groupId":"BG004","value":"45.6","spread":"10.83"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"93"},{"groupId":"BG003","value":"82"},{"groupId":"BG004","value":"214"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"123"},{"groupId":"BG003","value":"131"},{"groupId":"BG004","value":"319"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"66"},{"groupId":"BG004","value":"142"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"163"},{"groupId":"BG003","value":"146"},{"groupId":"BG004","value":"390"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"7"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"9"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"99"},{"groupId":"BG003","value":"81"},{"groupId":"BG004","value":"223"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"106"},{"groupId":"BG003","value":"121"},{"groupId":"BG004","value":"284"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"216"},{"groupId":"BG003","value":"213"},{"groupId":"BG004","value":"533"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7","description":"PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC\\[0-tau\\] on Day 7.","populationDescription":"The PK population included all enrolled participants who received at least one dose of study drug and had evaluable pharmacokinetic data for this specific outcome measure. As pre-specified in the statistical analysis plan, only participants with valid data from all three treatment periods (two capsule treatment and one tablet treatment) corresponding to the relevant dose level were included in the analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Nanogram* hours/milliliter (ng*h/ml)","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)","groups":[{"id":"OG000","title":"Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 1 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 1B were included in this arm."},{"id":"OG001","title":"Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 1 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 1B were included in this arm."},{"id":"OG002","title":"Cohort 1B: 0.8 mg LY3502970 Tablet QD","description":"Participants in Cohort 1B received LY3502970 administered orally once daily as a tablet at a dose of 0.8 mg (corresponding to the 1 mg capsule dose) were included in this arm."},{"id":"OG003","title":"Cohort 1B: 3 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 3 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 1B were included in this arm."},{"id":"OG004","title":"Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 3 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 1B were included in this arm."},{"id":"OG005","title":"Cohort 1B: 2.5 mg LY3502970 Tablet QD","description":"Participants in Cohort 1B received LY3502970 administered orally once daily as a tablet at a dose of 2.5 mg (corresponding to the 3 mg capsule dose) were included in this arm."},{"id":"OG006","title":"Cohort 1B: 6 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 6 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 1B were included in this arm."},{"id":"OG007","title":"Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 6 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 1B were included in this arm."},{"id":"OG008","title":"Cohort 1B: 5.5 mg LY3502970 Tablet QD","description":"Participants in Cohort 1B received LY3502970 administered orally once daily as a tablet at a dose of 5.5 mg (corresponding to the 6 mg capsule dose) were included in this arm."},{"id":"OG009","title":"Cohort 2B: 12 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 12 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 2B were included in this arm."},{"id":"OG010","title":"Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 12 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 2B were included in this arm."},{"id":"OG011","title":"Cohort 2B: 9 mg LY3502970 Tablet QD","description":"Participants in Cohort 2B received LY3502970 administered orally once daily as a tablet at a dose of 9 mg (corresponding to the 12 mg capsule dose) were included in this arm."},{"id":"OG012","title":"Cohort 2B: 24 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 24 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 2B were included in this arm."},{"id":"OG013","title":"Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 24 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 2B were included in this arm."},{"id":"OG014","title":"Cohort 2B: 14.5 mg LY3502970 Tablet QD","description":"Participants in Cohort 2B received LY3502970 administered orally once daily as a tablet at a dose of 14.5 mg (corresponding to the 24 mg capsule dose) were included in this arm."},{"id":"OG015","title":"Cohort 2B: 36 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 36 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 2B were included in this arm."},{"id":"OG016","title":"Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 36 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 2B were included in this arm."},{"id":"OG017","title":"Cohort 2B: 17.2 mg LY3502970 Tablet QD","description":"Participants in Cohort 2B received LY3502970 administered orally once daily as a tablet at a dose of 17.2 mg (corresponding to the 36 mg capsule dose) were included in this arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"211"},{"groupId":"OG003","value":"205"},{"groupId":"OG004","value":"204"},{"groupId":"OG005","value":"207"},{"groupId":"OG006","value":"196"},{"groupId":"OG007","value":"196"},{"groupId":"OG008","value":"199"},{"groupId":"OG009","value":"176"},{"groupId":"OG010","value":"179"},{"groupId":"OG011","value":"182"},{"groupId":"OG012","value":"175"},{"groupId":"OG013","value":"177"},{"groupId":"OG014","value":"179"},{"groupId":"OG015","value":"173"},{"groupId":"OG016","value":"170"},{"groupId":"OG017","value":"173"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","spread":"37.8"},{"groupId":"OG001","value":"82.1","spread":"39.7"},{"groupId":"OG002","value":"78.9","spread":"36.6"},{"groupId":"OG003","value":"240","spread":"38.8"},{"groupId":"OG004","value":"252","spread":"39.1"},{"groupId":"OG005","value":"247","spread":"37.3"},{"groupId":"OG006","value":"517","spread":"47.4"},{"groupId":"OG007","value":"541","spread":"60.4"},{"groupId":"OG008","value":"524","spread":"45.4"},{"groupId":"OG009","value":"829","spread":"46.4"},{"groupId":"OG010","value":"841","spread":"46.3"},{"groupId":"OG011","value":"790","spread":"40.3"},{"groupId":"OG012","value":"1210","spread":"50.0"},{"groupId":"OG013","value":"1260","spread":"57.5"},{"groupId":"OG014","value":"1200","spread":"64.2"},{"groupId":"OG015","value":"1500","spread":"71.5"},{"groupId":"OG016","value":"1500","spread":"71.9"},{"groupId":"OG017","value":"1520","spread":"60.4"}]}]}]},{"type":"PRIMARY","title":"Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7","description":"PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.","populationDescription":"The PK population included all enrolled participants who received at least one dose of study drug and had evaluable pharmacokinetic data for this specific outcome measure. As pre-specified in the statistical analysis plan, only participants with valid data from all three treatment periods (two capsule treatment and one tablet treatment) corresponding to the relevant dose level were included in the analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Nanogram per milliliter (ng/ml)","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)","groups":[{"id":"OG000","title":"Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 1 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 1B were included in this arm."},{"id":"OG001","title":"Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 1 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 1B were included in this arm."},{"id":"OG002","title":"Cohort 1B: 0.8 mg LY3502970 Tablet QD","description":"Participants in Cohort 1B received LY3502970 administered orally once daily as a tablet at a dose of 0.8 mg (corresponding to the 1 mg capsule dose) were included in this arm."},{"id":"OG003","title":"Cohort 1B: 3 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 3 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 1B were included in this arm."},{"id":"OG004","title":"Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 3 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 1B were included in this arm."},{"id":"OG005","title":"Cohort 1B: 2.5 mg LY3502970 Tablet QD","description":"Participants in Cohort 1B received LY3502970 administered orally once daily as a tablet at a dose of 2.5 mg (corresponding to the 3 mg capsule dose) were included in this arm."},{"id":"OG006","title":"Cohort 1B: 6 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 6 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 1B were included in this arm."},{"id":"OG007","title":"Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 6 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 1B were included in this arm."},{"id":"OG008","title":"Cohort 1B: 5.5 mg LY3502970 Tablet QD","description":"Participants in Cohort 1B received LY3502970 administered orally once daily as a tablet at a dose of 5.5 mg (corresponding to the 6 mg capsule dose) were included in this arm."},{"id":"OG009","title":"Cohort 2B: 12 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 12 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 2B were included in this arm."},{"id":"OG010","title":"Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 12 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 2B were included in this arm."},{"id":"OG011","title":"Cohort 2B: 9 mg LY3502970 Tablet QD","description":"Participants in Cohort 2B received LY3502970 administered orally once daily as a tablet at a dose of 9 mg (corresponding to the 12 mg capsule dose) were included in this arm."},{"id":"OG012","title":"Cohort 2B: 24 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 24 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 2B were included in this arm."},{"id":"OG013","title":"Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 24 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 2B were included in this arm."},{"id":"OG014","title":"Cohort 2B: 14.5 mg LY3502970 Tablet QD","description":"Participants in Cohort 2B received LY3502970 administered orally once daily as a tablet at a dose of 14.5 mg (corresponding to the 24 mg capsule dose were included in this arm."},{"id":"OG015","title":"Cohort 2B: 36 mg LY3502970 Capsule QD (First Treatment)","description":"Participants who received 36 mg LY3502970 administered orally once daily as a capsule during the first treatment of Cohort 2B were included in this arm."},{"id":"OG016","title":"Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment)","description":"Participants who received 36 mg LY3502970 administered orally once daily as a capsule during the second treatment of Cohort 2B were included in this arm."},{"id":"OG017","title":"Cohort 2B: 17.2 mg LY3502970 Tablet QD","description":"Participants in Cohort 2B received LY3502970 administered orally once daily as a tablet at a dose of 17.2 mg (corresponding to the 36 mg capsule dose) were included in this arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"211"},{"groupId":"OG003","value":"205"},{"groupId":"OG004","value":"204"},{"groupId":"OG005","value":"207"},{"groupId":"OG006","value":"196"},{"groupId":"OG007","value":"196"},{"groupId":"OG008","value":"200"},{"groupId":"OG009","value":"177"},{"groupId":"OG010","value":"179"},{"groupId":"OG011","value":"182"},{"groupId":"OG012","value":"175"},{"groupId":"OG013","value":"177"},{"groupId":"OG014","value":"179"},{"groupId":"OG015","value":"173"},{"groupId":"OG016","value":"170"},{"groupId":"OG017","value":"173"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.39","spread":"37.9"},{"groupId":"OG001","value":"5.60","spread":"39.5"},{"groupId":"OG002","value":"5.38","spread":"35.9"},{"groupId":"OG003","value":"16.2","spread":"41.2"},{"groupId":"OG004","value":"16.8","spread":"38.8"},{"groupId":"OG005","value":"16.8","spread":"37.4"},{"groupId":"OG006","value":"35.1","spread":"50.0"},{"groupId":"OG007","value":"36.8","spread":"63.6"},{"groupId":"OG008","value":"34.9","spread":"63.9"},{"groupId":"OG009","value":"55.0","spread":"55.0"},{"groupId":"OG010","value":"55.6","spread":"51.3"},{"groupId":"OG011","value":"53.5","spread":"41.7"},{"groupId":"OG012","value":"80.0","spread":"52.1"},{"groupId":"OG013","value":"82.6","spread":"60.6"},{"groupId":"OG014","value":"82.2","spread":"67.7"},{"groupId":"OG015","value":"96.9","spread":"74.4"},{"groupId":"OG016","value":"96.2","spread":"75.8"},{"groupId":"OG017","value":"105","spread":"65.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Cohort 1A: Baseline Up to end of follow up (Up to 13 weeks); Cohort 2A: Baseline Up to end of follow up (Up to 19 weeks); Cohort 1B: Baseline Up to end of follow up (Up to 10 weeks); Cohort 2B: Baseline Up to end of follow up (Up to 16 weeks).","description":"Safety population consisted of all participants who were exposed to at least 1 dose of study drug. As per the planned safety analysis, participants were analyzed as per the treatment they actually received. For Cohorts 2A and 2B, adverse events during the at-home dosing phase (Periods 1-6; sequential dose escalation of 1 mg, 3 mg, and 6 mg capsule) are pooled and reported as a single arm.","eventGroups":[{"id":"EG000","title":"Cohort 1A: 1 mg LY3502970 Capsule QD","description":"Participants who received 1 mg LY3502970 administered orally once daily as a capsule in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":6,"otherNumAtRisk":52},{"id":"EG001","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 1)","description":"Participants who received LY3502970 (dose level 1) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":8,"otherNumAtRisk":52},{"id":"EG002","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 2)","description":"Participants who received LY3502970 (dose level 2) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":7,"otherNumAtRisk":52},{"id":"EG003","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 3)","description":"Participants who received LY3502970 (dose level 3) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":9,"otherNumAtRisk":52},{"id":"EG004","title":"Cohort 1A: 3 mg LY3502970 Capsule QD","description":"Participants who received 3 mg LY3502970 administered orally once daily as a capsule in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":47,"seriousNumAffected":0,"seriousNumAtRisk":47,"otherNumAffected":6,"otherNumAtRisk":47},{"id":"EG005","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 4)","description":"Participants who received LY3502970 (dose level 4) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":51,"seriousNumAffected":0,"seriousNumAtRisk":51,"otherNumAffected":9,"otherNumAtRisk":51},{"id":"EG006","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 5)","description":"Participants who received LY3502970 (dose level 5) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":48,"seriousNumAffected":0,"seriousNumAtRisk":48,"otherNumAffected":10,"otherNumAtRisk":48},{"id":"EG007","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 6)","description":"Participants who received LY3502970 (dose level 6) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":51,"seriousNumAffected":0,"seriousNumAtRisk":51,"otherNumAffected":13,"otherNumAtRisk":51},{"id":"EG008","title":"Cohort 1A: 6 mg LY3502970 Capsule QD","description":"Participants who received 6 mg LY3502970 administered orally once daily as a capsule in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":46,"seriousNumAffected":0,"seriousNumAtRisk":46,"otherNumAffected":7,"otherNumAtRisk":46},{"id":"EG009","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 7)","description":"Participants who received LY3502970 (dose level 7) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":46,"seriousNumAffected":0,"seriousNumAtRisk":46,"otherNumAffected":6,"otherNumAtRisk":46},{"id":"EG010","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 8)","description":"Participants who received LY3502970 (dose level 8) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":47,"seriousNumAffected":0,"seriousNumAtRisk":47,"otherNumAffected":7,"otherNumAtRisk":47},{"id":"EG011","title":"Cohort 1A: LY3502970 Tablet QD (Dose Level 9)","description":"Participants who received LY3502970 (dose level 9) administered orally once daily as a tablet in Cohort 1A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":46,"seriousNumAffected":0,"seriousNumAtRisk":46,"otherNumAffected":10,"otherNumAtRisk":46},{"id":"EG012","title":"Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)","description":"Participants who received 1/3/6 mg LY3502970 administered orally once daily as a capsule in home dosing in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":11,"otherNumAtRisk":52},{"id":"EG013","title":"Cohort 2A: 12 mg LY3502970 Capsule QD","description":"Participants who received 12 mg LY3502970 administered orally once daily as a capsule in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":7,"otherNumAtRisk":50},{"id":"EG014","title":"Cohort 2A: LY3502970 Tablet QD (Dose Level 10)","description":"Participants who received LY3502970 (dose level 10) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":16,"otherNumAtRisk":50},{"id":"EG015","title":"Cohort 2A:LY3502970 Tablet QD (Dose Level 11)","description":"Participants who received LY3502970 (dose level 11) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":11,"otherNumAtRisk":50},{"id":"EG016","title":"Cohort 2A: LY3502970 Tablet QD (Dose Level 12)","description":"Participants who received LY3502970 (dose level 12) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":8,"otherNumAtRisk":50},{"id":"EG017","title":"Cohort 2A: 24 mg LY3502970 Capsule QD","description":"Participants who received 24 mg LY3502970 administered orally once daily as a capsule in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":13,"otherNumAtRisk":50},{"id":"EG018","title":"Cohort 2A: LY3502970 Tablet QD (Dose Level 13)","description":"Participants who received LY3502970 (dose level 13) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":49,"seriousNumAffected":1,"seriousNumAtRisk":49,"otherNumAffected":10,"otherNumAtRisk":49},{"id":"EG019","title":"Cohort 2A: LY3502970 Tablet QD (Dose Level 14)","description":"Participants who received LY3502970 (dose level 14) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":49,"seriousNumAffected":0,"seriousNumAtRisk":49,"otherNumAffected":13,"otherNumAtRisk":49},{"id":"EG020","title":"Cohort 2A: LY3502970 Tablet QD (Dose Level 15)","description":"Participants who received LY3502970 (dose level 15) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":10,"otherNumAtRisk":50},{"id":"EG021","title":"Cohort 2A: 36 mg LY3502970 Capsule QD","description":"Participants who received 36 mg LY3502970 administered orally once daily as a capsule in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":9,"otherNumAtRisk":45},{"id":"EG022","title":"Cohort 2A: LY3502970 Tablet QD (Dose Level 16)","description":"Participants who received LY3502970 (dose level 16) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":9,"otherNumAtRisk":45},{"id":"EG023","title":"Cohort 2A:LY3502970 Tablet QD (Dose Level 17)","description":"Participants who received LY3502970 (dose level 17) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":9,"otherNumAtRisk":45},{"id":"EG024","title":"Cohort 2A: LY3502970 Tablet QD (Dose Level 18)","description":"Participants who received LY3502970 (dose level 18) administered orally once daily as a tablet in Cohort 2A were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":9,"otherNumAtRisk":45},{"id":"EG025","title":"Cohort 1B: 1 mg LY3502970 Capsule QD","description":"Participants who received 1 mg LY3502970 administered orally once daily as a capsule in Cohort 1B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":215,"seriousNumAffected":0,"seriousNumAtRisk":215,"otherNumAffected":92,"otherNumAtRisk":215},{"id":"EG026","title":"Cohort 1B: 0.8 mg LY3502970 Tablet QD","description":"Participants who received 0.8 mg LY3502970 administered orally once daily as a tablet in Cohort 1B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":213,"seriousNumAffected":0,"seriousNumAtRisk":213,"otherNumAffected":49,"otherNumAtRisk":213},{"id":"EG027","title":"Cohort 1B: 3 mg LY3502970 Capsule QD","description":"Participants who received 3 mg LY3502970 administered orally once daily as a capsule in Cohort 1B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":210,"seriousNumAffected":0,"seriousNumAtRisk":210,"otherNumAffected":96,"otherNumAtRisk":210},{"id":"EG028","title":"Cohort 1B: 2.5 mg LY3502970 Tablet QD","description":"Participants who received 2.5 mg LY3502970 administered orally once daily as a tablet in Cohort 1B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":210,"seriousNumAffected":0,"seriousNumAtRisk":210,"otherNumAffected":57,"otherNumAtRisk":210},{"id":"EG029","title":"Cohort 1B: 6 mg LY3502970 Capsule QD","description":"Participants who received 6 mg LY3502970 administered orally once daily as a capsule in Cohort 1B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":203,"seriousNumAffected":1,"seriousNumAtRisk":203,"otherNumAffected":80,"otherNumAtRisk":203},{"id":"EG030","title":"Cohort 1B:5.5 mg LY3502970 Tablet QD","description":"Participants who received 5.5 mg LY3502970 administered orally once daily as a tablet in Cohort 1B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":203,"seriousNumAffected":1,"seriousNumAtRisk":203,"otherNumAffected":51,"otherNumAtRisk":203},{"id":"EG031","title":"Cohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing)","description":"Participants who received 1/3/6 mg LY3502970 administered orally once daily as a capsule in home dosing in Cohort 2B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":213,"seriousNumAffected":0,"seriousNumAtRisk":213,"otherNumAffected":111,"otherNumAtRisk":213},{"id":"EG032","title":"Cohort 2B:12 mg LY3502970 Capsule QD","description":"Participants who received 12 mg LY3502970 administered orally once daily as a capsule in Cohort 2B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":186,"seriousNumAffected":0,"seriousNumAtRisk":186,"otherNumAffected":97,"otherNumAtRisk":186},{"id":"EG033","title":"Cohort 2B:9 mg LY3502970 Tablet QD","description":"Participants who received 9 mg LY3502970 administered orally once daily as a tablet in Cohort 2B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":186,"seriousNumAffected":0,"seriousNumAtRisk":186,"otherNumAffected":61,"otherNumAtRisk":186},{"id":"EG034","title":"Cohort 2B:24 mg LY3502970 Capsule QD","description":"Participants who received 24 mg LY3502970 administered orally once daily as a capsule in Cohort 2B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":181,"seriousNumAffected":0,"seriousNumAtRisk":181,"otherNumAffected":85,"otherNumAtRisk":181},{"id":"EG035","title":"Cohort 2B:14.5 mg LY3502970 Tablet QD","description":"Participants who received LY3502970 14.5 mg administered orally once daily as a tablet in Cohort 2B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":180,"seriousNumAffected":0,"seriousNumAtRisk":180,"otherNumAffected":56,"otherNumAtRisk":180},{"id":"EG036","title":"Cohort 2B: 36 mg LY3502970 Capsule QD","description":"Participants who received 36 mg LY3502970 administered orally once daily as a capsule in Cohort 2B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":176,"seriousNumAffected":1,"seriousNumAtRisk":176,"otherNumAffected":66,"otherNumAtRisk":176},{"id":"EG037","title":"Cohort 2B: 17.2 mg LY3502970 Tablet QD","description":"Participants who received 17.2 mg LY3502970 administered orally once daily as a tablet in Cohort 2B were included in this arm.","deathsNumAffected":0,"deathsNumAtRisk":176,"seriousNumAffected":0,"seriousNumAtRisk":176,"otherNumAffected":35,"otherNumAtRisk":176}],"seriousEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":215},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":203},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":203},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":186},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":186},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":180},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":176},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":176}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":215},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG029","numEvents":1,"numAffected":1,"numAtRisk":203},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":203},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":186},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":186},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":180},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":176},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":176}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":49},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":215},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":203},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":203},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":186},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":186},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":180},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":176},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":176}]},{"term":"Oesophageal carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":215},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":203},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":203},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":186},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":186},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":180},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":176},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":176}]}],"otherEvents":[{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":1,"numAffected":1,"numAtRisk":215},{"groupId":"EG026","numEvents":2,"numAffected":2,"numAtRisk":213},{"groupId":"EG027","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG028","numEvents":2,"numAffected":2,"numAtRisk":210},{"groupId":"EG029","numEvents":6,"numAffected":6,"numAtRisk":203},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":203},{"groupId":"EG031","numEvents":17,"numAffected":13,"numAtRisk":213},{"groupId":"EG032","numEvents":7,"numAffected":6,"numAtRisk":186},{"groupId":"EG033","numEvents":3,"numAffected":3,"numAtRisk":186},{"groupId":"EG034","numEvents":9,"numAffected":9,"numAtRisk":181},{"groupId":"EG035","numEvents":6,"numAffected":6,"numAtRisk":180},{"groupId":"EG036","numEvents":2,"numAffected":2,"numAtRisk":176},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":176}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":51},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":48},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":49},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":2,"numAffected":2,"numAtRisk":215},{"groupId":"EG026","numEvents":2,"numAffected":2,"numAtRisk":213},{"groupId":"EG027","numEvents":3,"numAffected":3,"numAtRisk":210},{"groupId":"EG028","numEvents":2,"numAffected":2,"numAtRisk":210},{"groupId":"EG029","numEvents":7,"numAffected":7,"numAtRisk":203},{"groupId":"EG030","numEvents":2,"numAffected":2,"numAtRisk":203},{"groupId":"EG031","numEvents":4,"numAffected":4,"numAtRisk":213},{"groupId":"EG032","numEvents":5,"numAffected":5,"numAtRisk":186},{"groupId":"EG033","numEvents":2,"numAffected":2,"numAtRisk":186},{"groupId":"EG034","numEvents":7,"numAffected":6,"numAtRisk":181},{"groupId":"EG035","numEvents":1,"numAffected":1,"numAtRisk":180},{"groupId":"EG036","numEvents":5,"numAffected":5,"numAtRisk":176},{"groupId":"EG037","numEvents":1,"numAffected":1,"numAtRisk":176}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":52},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":52},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":51},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":48},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":51},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":6,"numAffected":5,"numAtRisk":52},{"groupId":"EG013","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG014","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG018","numEvents":4,"numAffected":4,"numAtRisk":49},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG022","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG024","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG025","numEvents":62,"numAffected":58,"numAtRisk":215},{"groupId":"EG026","numEvents":19,"numAffected":19,"numAtRisk":213},{"groupId":"EG027","numEvents":21,"numAffected":20,"numAtRisk":210},{"groupId":"EG028","numEvents":13,"numAffected":13,"numAtRisk":210},{"groupId":"EG029","numEvents":16,"numAffected":15,"numAtRisk":203},{"groupId":"EG030","numEvents":10,"numAffected":10,"numAtRisk":203},{"groupId":"EG031","numEvents":44,"numAffected":39,"numAtRisk":213},{"groupId":"EG032","numEvents":39,"numAffected":39,"numAtRisk":186},{"groupId":"EG033","numEvents":17,"numAffected":17,"numAtRisk":186},{"groupId":"EG034","numEvents":21,"numAffected":19,"numAtRisk":181},{"groupId":"EG035","numEvents":6,"numAffected":6,"numAtRisk":180},{"groupId":"EG036","numEvents":8,"numAffected":8,"numAtRisk":176},{"groupId":"EG037","numEvents":5,"numAffected":5,"numAtRisk":176}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":51},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":48},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG016","numEvents":5,"numAffected":2,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":49},{"groupId":"EG019","numEvents":3,"numAffected":2,"numAtRisk":49},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG021","numEvents":2,"numAffected":1,"numAtRisk":45},{"groupId":"EG022","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG023","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG024","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG025","numEvents":3,"numAffected":3,"numAtRisk":215},{"groupId":"EG026","numEvents":2,"numAffected":2,"numAtRisk":213},{"groupId":"EG027","numEvents":7,"numAffected":7,"numAtRisk":210},{"groupId":"EG028","numEvents":4,"numAffected":3,"numAtRisk":210},{"groupId":"EG029","numEvents":4,"numAffected":3,"numAtRisk":203},{"groupId":"EG030","numEvents":3,"numAffected":3,"numAtRisk":203},{"groupId":"EG031","numEvents":21,"numAffected":19,"numAtRisk":213},{"groupId":"EG032","numEvents":22,"numAffected":19,"numAtRisk":186},{"groupId":"EG033","numEvents":5,"numAffected":5,"numAtRisk":186},{"groupId":"EG034","numEvents":27,"numAffected":23,"numAtRisk":181},{"groupId":"EG035","numEvents":13,"numAffected":12,"numAtRisk":180},{"groupId":"EG036","numEvents":11,"numAffected":11,"numAtRisk":176},{"groupId":"EG037","numEvents":4,"numAffected":4,"numAtRisk":176}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":51},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":48},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":51},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG009","numEvents":3,"numAffected":2,"numAtRisk":46},{"groupId":"EG010","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG011","numEvents":2,"numAffected":1,"numAtRisk":46},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG015","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":49},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":8,"numAffected":8,"numAtRisk":215},{"groupId":"EG026","numEvents":10,"numAffected":10,"numAtRisk":213},{"groupId":"EG027","numEvents":12,"numAffected":12,"numAtRisk":210},{"groupId":"EG028","numEvents":13,"numAffected":12,"numAtRisk":210},{"groupId":"EG029","numEvents":19,"numAffected":16,"numAtRisk":203},{"groupId":"EG030","numEvents":9,"numAffected":9,"numAtRisk":203},{"groupId":"EG031","numEvents":19,"numAffected":16,"numAtRisk":213},{"groupId":"EG032","numEvents":18,"numAffected":14,"numAtRisk":186},{"groupId":"EG033","numEvents":9,"numAffected":9,"numAtRisk":186},{"groupId":"EG034","numEvents":13,"numAffected":13,"numAtRisk":181},{"groupId":"EG035","numEvents":7,"numAffected":7,"numAtRisk":180},{"groupId":"EG036","numEvents":8,"numAffected":8,"numAtRisk":176},{"groupId":"EG037","numEvents":6,"numAffected":5,"numAtRisk":176}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":49},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":1,"numAffected":1,"numAtRisk":215},{"groupId":"EG026","numEvents":1,"numAffected":1,"numAtRisk":213},{"groupId":"EG027","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG028","numEvents":2,"numAffected":2,"numAtRisk":210},{"groupId":"EG029","numEvents":1,"numAffected":1,"numAtRisk":203},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":203},{"groupId":"EG031","numEvents":8,"numAffected":8,"numAtRisk":213},{"groupId":"EG032","numEvents":7,"numAffected":6,"numAtRisk":186},{"groupId":"EG033","numEvents":4,"numAffected":4,"numAtRisk":186},{"groupId":"EG034","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG035","numEvents":1,"numAffected":1,"numAtRisk":180},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":176},{"groupId":"EG037","numEvents":2,"numAffected":2,"numAtRisk":176}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG005","numEvents":5,"numAffected":4,"numAtRisk":51},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":48},{"groupId":"EG007","numEvents":5,"numAffected":2,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG011","numEvents":7,"numAffected":5,"numAtRisk":46},{"groupId":"EG012","numEvents":9,"numAffected":7,"numAtRisk":52},{"groupId":"EG013","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG014","numEvents":4,"numAffected":3,"numAtRisk":50},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG016","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":49},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":49},{"groupId":"EG020","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":6,"numAffected":6,"numAtRisk":45},{"groupId":"EG024","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG025","numEvents":14,"numAffected":13,"numAtRisk":215},{"groupId":"EG026","numEvents":7,"numAffected":7,"numAtRisk":213},{"groupId":"EG027","numEvents":29,"numAffected":29,"numAtRisk":210},{"groupId":"EG028","numEvents":13,"numAffected":13,"numAtRisk":210},{"groupId":"EG029","numEvents":19,"numAffected":19,"numAtRisk":203},{"groupId":"EG030","numEvents":17,"numAffected":17,"numAtRisk":203},{"groupId":"EG031","numEvents":54,"numAffected":44,"numAtRisk":213},{"groupId":"EG032","numEvents":37,"numAffected":32,"numAtRisk":186},{"groupId":"EG033","numEvents":13,"numAffected":12,"numAtRisk":186},{"groupId":"EG034","numEvents":31,"numAffected":31,"numAtRisk":181},{"groupId":"EG035","numEvents":15,"numAffected":15,"numAtRisk":180},{"groupId":"EG036","numEvents":9,"numAffected":9,"numAtRisk":176},{"groupId":"EG037","numEvents":6,"numAffected":6,"numAtRisk":176}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":51},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":48},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":51},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG009","numEvents":2,"numAffected":1,"numAtRisk":46},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG011","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG012","numEvents":5,"numAffected":4,"numAtRisk":52},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG017","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG018","numEvents":3,"numAffected":2,"numAtRisk":49},{"groupId":"EG019","numEvents":3,"numAffected":2,"numAtRisk":49},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG021","numEvents":4,"numAffected":1,"numAtRisk":45},{"groupId":"EG022","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG023","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG025","numEvents":4,"numAffected":4,"numAtRisk":215},{"groupId":"EG026","numEvents":5,"numAffected":4,"numAtRisk":213},{"groupId":"EG027","numEvents":33,"numAffected":16,"numAtRisk":210},{"groupId":"EG028","numEvents":14,"numAffected":7,"numAtRisk":210},{"groupId":"EG029","numEvents":28,"numAffected":15,"numAtRisk":203},{"groupId":"EG030","numEvents":12,"numAffected":10,"numAtRisk":203},{"groupId":"EG031","numEvents":32,"numAffected":24,"numAtRisk":213},{"groupId":"EG032","numEvents":31,"numAffected":22,"numAtRisk":186},{"groupId":"EG033","numEvents":16,"numAffected":15,"numAtRisk":186},{"groupId":"EG034","numEvents":32,"numAffected":17,"numAtRisk":181},{"groupId":"EG035","numEvents":10,"numAffected":9,"numAtRisk":180},{"groupId":"EG036","numEvents":38,"numAffected":19,"numAtRisk":176},{"groupId":"EG037","numEvents":13,"numAffected":10,"numAtRisk":176}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":49},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":49},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":3,"numAffected":3,"numAtRisk":215},{"groupId":"EG026","numEvents":3,"numAffected":3,"numAtRisk":213},{"groupId":"EG027","numEvents":8,"numAffected":8,"numAtRisk":210},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG029","numEvents":2,"numAffected":2,"numAtRisk":203},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":203},{"groupId":"EG031","numEvents":13,"numAffected":12,"numAtRisk":213},{"groupId":"EG032","numEvents":7,"numAffected":7,"numAtRisk":186},{"groupId":"EG033","numEvents":2,"numAffected":2,"numAtRisk":186},{"groupId":"EG034","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG035","numEvents":2,"numAffected":2,"numAtRisk":180},{"groupId":"EG036","numEvents":2,"numAffected":2,"numAtRisk":176},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":176}]},{"term":"Heart rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":49},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG022","numEvents":5,"numAffected":4,"numAtRisk":45},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":215},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG027","numEvents":4,"numAffected":3,"numAtRisk":210},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG029","numEvents":1,"numAffected":1,"numAtRisk":203},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":203},{"groupId":"EG031","numEvents":5,"numAffected":5,"numAtRisk":213},{"groupId":"EG032","numEvents":5,"numAffected":3,"numAtRisk":186},{"groupId":"EG033","numEvents":4,"numAffected":2,"numAtRisk":186},{"groupId":"EG034","numEvents":5,"numAffected":5,"numAtRisk":181},{"groupId":"EG035","numEvents":2,"numAffected":2,"numAtRisk":180},{"groupId":"EG036","numEvents":7,"numAffected":5,"numAtRisk":176},{"groupId":"EG037","numEvents":5,"numAffected":4,"numAtRisk":176}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":48},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":51},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG025","numEvents":8,"numAffected":8,"numAtRisk":215},{"groupId":"EG026","numEvents":4,"numAffected":4,"numAtRisk":213},{"groupId":"EG027","numEvents":15,"numAffected":15,"numAtRisk":210},{"groupId":"EG028","numEvents":3,"numAffected":3,"numAtRisk":210},{"groupId":"EG029","numEvents":3,"numAffected":3,"numAtRisk":203},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":203},{"groupId":"EG031","numEvents":47,"numAffected":43,"numAtRisk":213},{"groupId":"EG032","numEvents":1,"numAffected":1,"numAtRisk":186},{"groupId":"EG033","numEvents":5,"numAffected":5,"numAtRisk":186},{"groupId":"EG034","numEvents":4,"numAffected":4,"numAtRisk":181},{"groupId":"EG035","numEvents":5,"numAffected":5,"numAtRisk":180},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":176},{"groupId":"EG037","numEvents":2,"numAffected":2,"numAtRisk":176}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":51},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":48},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":51},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":49},{"groupId":"EG019","numEvents":6,"numAffected":6,"numAtRisk":49},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG023","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG025","numEvents":2,"numAffected":2,"numAtRisk":215},{"groupId":"EG026","numEvents":2,"numAffected":2,"numAtRisk":213},{"groupId":"EG027","numEvents":4,"numAffected":4,"numAtRisk":210},{"groupId":"EG028","numEvents":3,"numAffected":3,"numAtRisk":210},{"groupId":"EG029","numEvents":5,"numAffected":5,"numAtRisk":203},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":203},{"groupId":"EG031","numEvents":8,"numAffected":7,"numAtRisk":213},{"groupId":"EG032","numEvents":11,"numAffected":9,"numAtRisk":186},{"groupId":"EG033","numEvents":3,"numAffected":3,"numAtRisk":186},{"groupId":"EG034","numEvents":9,"numAffected":8,"numAtRisk":181},{"groupId":"EG035","numEvents":6,"numAffected":6,"numAtRisk":180},{"groupId":"EG036","numEvents":7,"numAffected":6,"numAtRisk":176},{"groupId":"EG037","numEvents":5,"numAffected":3,"numAtRisk":176}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":51},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":48},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":51},{"groupId":"EG008","numEvents":5,"numAffected":4,"numAtRisk":46},{"groupId":"EG009","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG011","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG012","numEvents":5,"numAffected":5,"numAtRisk":52},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG014","numEvents":4,"numAffected":3,"numAtRisk":50},{"groupId":"EG015","numEvents":3,"numAffected":2,"numAtRisk":50},{"groupId":"EG016","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG017","numEvents":5,"numAffected":5,"numAtRisk":50},{"groupId":"EG018","numEvents":2,"numAffected":1,"numAtRisk":49},{"groupId":"EG019","numEvents":3,"numAffected":3,"numAtRisk":49},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG022","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG023","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG025","numEvents":41,"numAffected":34,"numAtRisk":215},{"groupId":"EG026","numEvents":20,"numAffected":19,"numAtRisk":213},{"groupId":"EG027","numEvents":41,"numAffected":37,"numAtRisk":210},{"groupId":"EG028","numEvents":18,"numAffected":17,"numAtRisk":210},{"groupId":"EG029","numEvents":27,"numAffected":25,"numAtRisk":203},{"groupId":"EG030","numEvents":22,"numAffected":17,"numAtRisk":203},{"groupId":"EG031","numEvents":30,"numAffected":23,"numAtRisk":213},{"groupId":"EG032","numEvents":46,"numAffected":36,"numAtRisk":186},{"groupId":"EG033","numEvents":21,"numAffected":18,"numAtRisk":186},{"groupId":"EG034","numEvents":19,"numAffected":18,"numAtRisk":181},{"groupId":"EG035","numEvents":16,"numAffected":15,"numAtRisk":180},{"groupId":"EG036","numEvents":32,"numAffected":28,"numAtRisk":176},{"groupId":"EG037","numEvents":6,"numAffected":6,"numAtRisk":176}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800- 545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2024-08-14","uploadDate":"2026-04-16T17:40","filename":"Prot_000.pdf","size":8630487},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2025-03-10","uploadDate":"2026-04-16T17:41","filename":"SAP_001.pdf","size":1091834}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"},{"id":"D050177","term":"Overweight"}],"ancestors":[{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000729680","term":"orforglipron"}]}},"hasResults":true}